{"id":"doi:10.1093/haschl/qxag231","kind":"article","title":"\"Am I a candidate for magic mushrooms?\" A mystery shopper study of Oregon psilocybin service centers","authors":["Adams DR","Hartman M","Gong L","Shankar S","Ling R","Steinle JT","Siegel JS","Nicol GE","Grucza RA","Borodovsky JT","Cabassa LJ","Xu KY"],"author_count":12,"year":2026,"published":"2026-08-27","venue":"Health affairs scholar","cited_by":0,"doi":"10.1093/haschl/qxag231","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1093/haschl/qxag231","archive_url":"https://space-kitty.com/papers/doi:10.1093/haschl/qxag231","updated":null,"pmid":"42871231","pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"Introduction Oregon is the first US state to permit supervised psilocybin services through a nonmedical, wellness-based model. We examined what prospective clients with psychiatric histories encounter when contacting service centers, including how staff communicate about safety, eligibility, and cost. Methods We conducted a mystery shopper study of 26 licensed service centers in Oregon (7/2025-9/2025), 4 of which closed before calls began, leaving 22 in the sample. We reviewed websites and conducted 2 waves of scripted phone calls portraying adults with depression. Website and call data were combined at the center level, counting an item as disclosed if it appeared online or during a call. Themes from call field notes were contextualized through structured debriefing interviews with service center staff. Results Callers reached 15/22 centers, none of which permitted unsupervised consumption or immediate dosing without psychiatric assessment. Staff asked detailed questions about psychiatric comorbidities, addressing information gaps from websites, and none recommended discontinuing antidepressants. The median cost was $1900. Debriefing interviews described financial strain for service centers, with viability constrained by licensing fees and potential misalignment with cannabis-derived business models. Conclusion Oregon's regulated model appears clinically cautious, while facing high costs for clients, facilitators, and service centers that limit scalability.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"\"Am I a candidate for magic mushrooms?\" A mystery shopper study of Oregon psilocybin service centers\" by Adams DR, Hartman M, Gong L et al., https://doi.org/10.1093/haschl/qxag231, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"psychiatric-therapeutics","name":"Novel Psychiatric Therapeutics","domain_slug":"neuroscience"}],"cited_in_dossiers":[{"slug":"psychiatric-therapeutics","title":"Novel Psychiatric Therapeutics: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/psychiatric-therapeutics"}]}